Paysign, Inc. (PAYS)
| Market Cap | 456.75M |
| Revenue (ttm) | 91.47M |
| Net Income (ttm) | 10.40M |
| Shares Out | 55.91M |
| EPS (ttm) | 0.17 |
| PE Ratio | 47.61 |
| Forward PE | 35.52 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 2,668,114 |
| Open | 7.68 |
| Previous Close | 7.72 |
| Day's Range | 7.68 - 8.21 |
| 52-Week Range | 3.08 - 8.88 |
| Beta | 0.74 |
| Analysts | Strong Buy |
| Price Target | 9.95 (+21.79%) |
| Earnings Date | Aug 4, 2026 |
About PAYS
Paysign, Inc. provides prepaid card programs, patient affordability offerings, digital banking, life science software technology solutions, and integrated payment processing services for businesses, consumers, and government institutions in the United States. The company offers solutions for corporate rewards, prepaid gift cards, general-purpose reloadable debit cards, employee incentives, consumer rebates, donor compensation, clinical trials, healthcare reimbursement payments and pharmaceutical payment assistance, and demand deposit accounts a... [Read more]
Financial Performance
In 2025, Paysign's revenue was $82.03 million, an increase of 40.50% compared to the previous year's $58.38 million. Earnings were $7.55 million, an increase of 97.90%.
Financial StatementsAnalyst Forecast
According to 5 analysts, the average rating for PAYS stock is "Strong Buy." The 12-month stock price target is $9.95, which is an increase of 21.79% from the latest price.
News
Paysign Transcript: Planet MicroCap Las Vegas 2026
Strong revenue and EBITDA growth driven by both plasma and patient affordability businesses, with proprietary technology providing a competitive edge and significant cost savings for clients. Market leadership, regulatory compliance, and a scalable platform position the company for continued expansion.
Paysign Slides: FY 2026
Paysign has posted slides in relation to its FY 2026 quarterly earnings report, which was published on June 17, 2026.
Paysign Transcript: 16th Annual East Coast IDEAS Conference
A leading provider of plasma donor payments and pharma co-pay solutions, the company is experiencing rapid growth in its patient affordability business, driving margin expansion and a shift in revenue mix. Proprietary technology and regulatory compliance underpin its competitive edge.
Paysign Slides: 16th Annual East Coast IDEAS Conference
Paysign has posted slides in relation to its latest quarterly earnings report, which was published on June 11, 2026.
Paysign management to meet with Lake Street
Meeting to be held in Las Vegas on June 16 hosted by Lake Street.
Paysign, Inc. to Present at the Planet MicroCap Las Vegas 2026
HENDERSON, Nev.--(BUSINESS WIRE)--Paysign, Inc. to Present at the Planet MicroCap Las Vegas 2026.
Paysign management to meet with Lake Street
Meeting to be held in San Francisco on June 2 hosted by Lake Street.
Paysign, Inc. to Present at the Barrington Research Virtual Spring Investment Conference
HENDERSON, Nev.--(BUSINESS WIRE)--Paysign, Inc. to Present at the Barrington Research Virtual Spring Investment Conference.
Paysign Slides: Conference presentation
Paysign has posted slides in relation to its latest quarterly earnings report, which was published on May 18, 2026.
Paysign reports Q1 EPS 9c vs. 5c last year
Reports Q1 revenue $28.04M vs. $18.6M last year. “Paysign (PAYS) delivered a strong start to 2026, with exceptional top- and bottom-line results that are consistent with our strategic direction and…
Paysign sees FY26 EPS 21c-26c
Sees revenue $106.5M-$110.5M. Sees adjusted EBITDA $30M-$33M. “Our first quarter results exceeded guidance across every line of the income statement,” commented Jeff Baker, Chief Financial Officer of ...
Paysign sees Q2 EPS 6c-7c
Sees Q2 revenue $26.2M-$26.7M. Sees Q2 adjusted EBITDA $7.7M-$8.5M.
Paysign Earnings Call Transcript: Q1 2026
Record Q1 results with revenue up 50.8% and net income up 110% year-over-year, driven by strong growth in patient affordability and plasma segments. Guidance raised for 2026, with robust pipelines and no expected impact from plasma center closures.
Paysign Earnings release: Q1 2026
Paysign released its Q1 2026 earnings on May 12, 2026, summarizing the period's financial results.
Paysign Quarterly report: Q1 2026
Paysign has published its Q1 2026 quarterly earnings report on May 12, 2026.
Paysign's Patient Affordability Drives 51% Revenue Growth and Significant Margin Expansion for First Quarter 2026
HENDERSON, Nev.--(BUSINESS WIRE)--Paysign's Patient Affordability Drives 51% Revenue Growth and Significant Margin Expansion for First Quarter 2026.
Paysign management to meet with Barrington
Meeting to be held in Minneapolis on May 18 hosted by Barrington.
Paysign to Host First Quarter 2026 Earnings Call
HENDERSON, Nev.--(BUSINESS WIRE)--Paysign to Host First Quarter 2026 Earnings Call.
Paysign Proxy statement: Proxy filing
Paysign filed a proxy statement on March 26, 2026, providing details for shareholder voting and corporate governance matters.
Paysign Proxy statement: Proxy filing
Paysign filed a proxy statement on March 26, 2026, providing details for shareholder voting and corporate governance matters.
Paysign price target raised to $11 from $10 at Lake Street
Lake Street analyst Jacob Stephan raised the firm’s price target on Paysign (PAYS) to $11 from $10 and keeps a Buy rating on the shares. The firm, which is raising…
Paysign Earnings Call Transcript: Q4 2025
Revenue grew 40.5% to $82M in 2025, with net income up 98% and strong margin expansion. Patient Affordability revenue surged 168%, and 2026 guidance calls for 30–35% growth, driven by both plasma and pharma segments.
Paysign Annual report: Q4 2025
Paysign has published its Q4 2025 annual report on March 24, 2026.
Paysign Earnings release: Q4 2025
Paysign released its Q4 2025 earnings on March 24, 2026, summarizing the period's financial results.
Paysign reports Q4 adjusted EPS 9c, consensus 3c
Reports Q4 revenue $22.76M, consensus $21.55M. “2025 was a standout year for Paysign (PAYS), delivering record top- and bottom-line results,” commented Mark Newcomer, President and CEO of Paysign. “We...